Form 4: Lifecore Biomedical Director Joshua Schechter Acquires 30,000 Shares of Common Stock

Director Joshua Schechter reports acquiring 30,000 shares of Lifecore Biomedical common stock through restricted stock units.

Summary

• On July 8, 2024, Joshua Schechter, a director of Lifecore Biomedical, Inc., acquired 30,000 shares of common stock.
• The acquisition was in the form of restricted stock units (RSUs) that convert into common stock on a 1-for-1 basis.
• These RSUs vest on the earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.
• Following the transaction, Schechter directly owns 87,667 shares of common stock and indirectly owns 2,000 shares through a spouse.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the acquisition of shares by a director is generally a positive sign, it's a routine transaction and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the restricted stock units is contingent upon future events, specifically the passage of time and the occurrence of the annual meeting of stockholders.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates a director's recent acquisition of company stock.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates